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Organs are composed of highly diﬀerentiated, very specialized parenchy-
mal cells surrounded by stroma consisting of extracellular matrix, tissue
ﬂuid, and undiﬀerentiated pluripotent mesenchymal cells. Parenchymal cells
distinguish one organ from another based on their unique morphologic
features and their highly specialized functions. Disproportionate stromal
growth, relative to parenchymal growth, termed ‘‘ﬁbrosis’’ (sclerosis or cirr-
hosis), represents a pathologic structural remodeling of an organ [1].
Fibrosis presents in several diﬀerent morphologic patterns. A reparative
(replacement) ﬁbrosis appears at sites of parenchymal cell loss. For example,
microscopic scarring of ventricular myocardium follows cardiac myocyte
necrosis [2–4], whereas a macroscopic scar follows segmental infarction
[5,6]. A perivascular ﬁbrosis of intramural vessels with extensions into the
contiguous interstitial space has been referred to as a ‘‘reactive ﬁbrosis’’
because loss of parenchyma is not a requisite [7]. A perivascular-interstitial
ﬁbrosis, for example, accompanies chronic elevations in the eﬀector hor-
mones of the renin-angiotensin-aldosterone system [8–11].
Absolute ﬁbrosis is deﬁned as increased collagen concentration of an
organ and consists predominantly of ﬁbrillar collagen types I and III that
appear secondary to altered collagen turnover (synthesis greater than degra-
dation). Collectively, ﬁbrosis is a common pathway to organ failure. This
holds true for such diverse organs as the heart [12,13], kidneys [14,15], lungs
[16,17], and liver [18].
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the repair process has been completed. This is related to ﬁbrillar collagen
degradation by matrix metalloproteinases [19,20]. In other cases, there is
a persistent ﬁbrosis (eg, infarct scar of the myocardium) that is essential for
organ integrity. Lastly, a progressive ﬁbrosis can occur (eg, experimental
glomerulonephritis, chronic elevation of circulating angiotensin II [ANGII]
or aldosterone) and destroys organ architecture and accounts for its failure
[20–23]. The need to prevent ﬁbrosis or to regress it, once formed, represents
a major challenge. Various strategies can be taken [14].
Myocardial ﬁbrosis in hypertensive heart disease
Clinical evidence
The essential criterion in deﬁning hypertensive heart disease (HHD) is a
greater than normal heart mass in the absence of a cause other than arterial
hypertension. It is now accepted, however, that besides left ventricular hyper-
trophy (LVH), alterations in myocardial structure as listed below account for
loss of tissue homogeneity and pathologic remodeling that appears in HHD:
Cellular alterations
Cardiomyocytes
Hypertrophy, atrophy, apoptosis, necrosis
Noncardiomyocytes
Hyperplasia and apoptosis of ﬁbroblasts
Hypertrophy or hyperplasia of vascular smooth muscle cells
Noncellular alterations
Interstitial and perivascular ﬁbrosis
Microscopic scarring
Medial thickening of coronary arterioles
Diminished number of capillaries
A growing body of evidence indicates that myocardial ﬁbrosis is one of
the key pathologic features of myocardial remodeling in HHD. In fact,
a number of studies performed in postmortem human hearts [24–26] and
endomyocardial human biopsies [27–30] have shown that myocardial col-
lagen volume fraction, a morphometric measure of the amount of tissue
collagen, is constantly increased in patients with HHD compared with nor-
motensive controls (Fig. 1). Furthermore, an exaggerate accumulation of
ﬁbrillar collagen types I and III within the myocardial interstitium and
surrounding intramural coronary arteries and arterioles has been evidenced
immunohistochemically in patients with HHD [31].
Potential mechanisms
Collagen types I and III are the major ﬁbrillar collagens produced by
ﬁbroblasts in the adult heart. They exhibit the characteristic triple helical
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lagen of the heart provides the structural scaﬀolding for cardiomyocytes and
coronary vessels and imparts cardiac tissue with physical properties that
include stiﬀness and resistance to deformation [12]. In addition, ﬁbrillar
collagen may also act as a link between contractile element of adjacent
cardiomyocytes and as a conduit of information that is necessary for cell
function.
As in other organs, collagen turnover of normal adult heart results from
the equilibrium between the synthesis and degradation of collagen types I
and III molecules [32]. The synthesis of collagen molecules follows the
Fig. 1. (A) Histologic sections of interventricular septal specimen biopsies from humans.
Sections were stained with picrosirius red, and the interstitial collagen was identiﬁed in red
(original magniﬁcation 20). (B) Collagen volume fraction (CVF) determined in interventric-
ular septal specimen biopsies from humans. (Adapted from Querejeta R, Varo N, Lo´pez B,
Larman M, Artin˜ano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen
type I is a marker of myocardial ﬁbrosis in hypertensive heart disease. Circulation
2000;101:1729–35; with permission.)
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proteins in that the newly formed a chains undergo a number of post-
translational modiﬁcations. Extracellular degradation of collagen ﬁbers is
mediated by collagenase and other members of the matrix metalloprotein-
ase family of zinc-containing endoproteinases. The active form of collagenase
can be inhibited by interaction with naturally occurring speciﬁc tissue inhib-
itors of matrix metalloproteinases (TIMPs).
As shown by in vivo experiments, chronic pressure overload stimulates
both procollagen gene expression and collagen protein synthesis leading to
excessive collagen deposition and ﬁbrosis [33]. In addition, in vitro studies
have shown that procollagen type I synthesis is stimulated in cardiac ﬁbro-
blasts submitted to cyclic mechanical load [33]. Hemodynamic overload of
the left ventricle caused by systemic hypertension may play a role in myo-
cardial ﬁbrosis.
Nevertheless, two types of ﬁndings suggest that besides the mechanic
factor, nonhemodynamic factors may also contribute to myocardial ﬁbro-
sis in human hypertension. First, myocardial ﬁbrosis has been found not
only in the left ventricle but also in the right ventricle [25,34] and the
interventricular septum [35] in postmortem studies of human hearts with
HHD. Second, recent studies have shown that the ability of antihypertensive
treatment to regress ﬁbrosis in hypertensives with biopsy-proved myocardial
ﬁbrosis is independent of its antihypertensive eﬃcacy [29,36]. The current
view is that myocardial ﬁbrosis may be the consequence of the loss of
reciprocal regulation that normally exists between molecules that stimulate
(eg, ANGII) and molecules that inhibit ﬁbrillar collagen turnover [37].
Factors modulating collagen types I and III turnover in the myocardium
include the following:
Factors that facilitate the synthesis of collagen
Vasoactive substances
Angiotensin II, endothelin-1, catecholamines
Growth factors
Transforming growth factor-b1, platelet-derived growth factor, basic
ﬁbroblast growth factor, insulin-like growth factor-1
Hormones
Aldosterone, deoxycorticosterone
Cytokines
Interleukin-1
Adhesion molecules
Ostepontin
Factors that facilitate the degradation of collagen
Vasoactive substances
Bradykinin, prostaglandins, nitric oxide, natriuretic peptides
Growth factors
Hepatocyte growth factor
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Glucocorticoids
Cytokines
Tumoral necrosis factor-a, interferon-c
Endogenous peptides
N-acetyl-seryl-aspartyl-lysyl-proline
An excess of stimulators, caused by either absolute stimulator over-
production or by their relative overabundance because of a deﬁcit in inhib-
itor formation can promote ﬁbrosis.
Clinical impact
Several arguments support the concept that myocardial ﬁbrosis has a
particularly important inﬂuence in the process of heart failure associated
with cardiac remodeling [38]. First, interstitial ﬁbrosis contributes to ven-
tricular wall stiﬀness and consequently impairs cardiac compliance, con-
tributing to impaired diastolic function. Second, because neither the collagen
network nor the ﬁbroblasts contribute to systolic contraction, increased
collagen deposition and ﬁbroblast volume means that systolic work is being
performed by a smaller proportion of the cardiac mass, contributing to
systolic dysfunction. Third, perivascular ﬁbrosis leads to increased distance
that oxygen must diﬀuse and potentially lowers PaO2 for the working car-
diomyocytes. Finally, electrical coupling on the cardiomyocytes may be im-
paired by the accumulation of collagen proteins and ﬁbroblasts because
such accumulation causes morphologic separation of cardiomyocytes.
Role of angiotensin II in myocardial ﬁbrosis
Various lines of evidence support a role for ANGII as a critical candidate
factor to induce myocardial ﬁbrosis in HHD.
In vivo evidence
Animal models
Endogenous elevations in circulating ANGII that accompany unilateral
renal artery stenosis [39] or the infusion of exogenous ANGII [40] are
associated with increased blood pressure and ﬁbrosis. The appearance of
such ﬁbrous tissue formation is preceded by increased expression of ANGII
type 1 (AT1) receptors, transforming growth factor-b1 (TGF-b1), and
mRNA for collagen types I and III [41]. In addition, development of ﬁbrosis
involves proliferating ﬁbroblasts and cell diﬀerentiation into myoﬁbroblasts
[42]. Two observations suggest that the ability of ANGII to induce cardiac
ﬁbrosis in these models is independent of its hypertensive action. First,
ﬁbrosis in the renal artery stenosis model develops in both low-pressure
right and left atria and right ventricle and high-pressure left ventricle [43].
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either angiotensin converting enzyme (ACE) inhibitors or AT1 receptor
antagonists, but not hydralazine or prazosin, despite a similar antihyper-
tensive eﬃcacy of these compounds [44,45]. The critical role of ANGII in
hypertension-associated cardiac ﬁbrosis is further supported by the observa-
tion that experimental infrarenal aortic binding, which does not induce
ANGII, causes blood pressure elevation and cardiomyocyte hypertrophy
but not cardiac ﬁbrosis [43].
The hypertensive Ren2 rat provides a well-established model of ANGII-
dependent cardiac hypertrophy [46]. Several studies have revealed that
interstitial and perivascular ﬁbrosis, along with extensive collagen types I and
III deposition are present inRen2 [47–49]. Increased cardiac renin andANGII
levels have been described in this transgenic rat model [46]. In addition,
cardiac lesions are very sensitive to ACE inhibition and AT1 receptor
antagonism in Ren2 rats [50]. As a result, the development of hypertrophy
and ﬁbrosis in the heart of these animals has been attributed, at least partially,
to a local activation of the cardiac renin-angiotensin system.
Pharmacologic studies
Experimental ﬁndings. Pharmacologic interventions with ACE inhibitors or
AT1 receptor antagonists have underscored the potential importance of
ANGII in the mediation of cardiac ﬁbrosis in pathologic conditions, such as
primary hypertension. In rats with spontaneous hypertension and LVH,
myocardial ﬁbrosis has been shown to regress by treatment with the ACE
inhibitor lisinopril [51]. This eﬀect occurred independently of the drug’s
antihypertensive eﬀect [51]. It has been found that chronic AT1 receptor
antagonism with losartan resulted in reversal of ﬁbrosis, inhibition of the
posttranscriptional synthesis of procollagen type I, inhibition of TIMP-1
expression, and stimulation of collagenase activity in the left ventricle of
adult rats with spontaneous hypertension [52,53]. Analysis of the individual
data showed that the intensity of these myocardial changes was independent
of the antihypertensive eﬃcacy of the drug [52,53].
Clinical ﬁndings. The ﬁbrogenic role of ANGII in humans has been in-
vestigated in three recent prospective trials of limited size using biopsy-
proved myocardial ﬁbrosis in patients with essential hypertension and LVH.
Schwartzkopﬀ et al [28] studied 14 patients before and after 1 year of
treatment with the ACE inhibitor perindopril. Structural analysis revealed
diminution of perivascular and interstitial ﬁbrosis with treatment. The ob-
served regression of ﬁbrosis on ACE inhibitor treatment was observed in
the non–pressure-overloaded right ventricle, indicating that the antiﬁbrotic
eﬀect was not accounted for by left ventricular pressure reduction alone.
Brilla et al [29] randomized 35 previously treated patients with controlled
blood pressure to receive either the ACE inhibitor lisinopril or the diuretic
hydrochlorothiazide for 6 months. Only patients randomized to lisinopril
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was similar in patients treated with either lisinopril or hydrochlorothiazide.
Finally, Lo´pez et al [36] studied 37 treated patients with uncontrolled blood
pressure. After randomization, 21 patients were assigned to the AT1 receptor
antagonist losartan and 16 to the calcium channel blocker amlodipine for
12 months. Whereas myocardial ﬁbrosis decreased signiﬁcantly in losartan-
treated patients, this parameter remained unchanged in amlodipine-treated
patients. A similar reduction of blood pressure in losartan-treated patients
than in amlodipine-treated patients was reported in this study. Collectively,
these observations support the concept that in addition to pressure overload,
ANGII induces myocardial ﬁbrosis in essential hypertension.
Cellular and molecular mechanisms
Increasing evidence strongly indicates that ANGII exerts multiple pro-
ﬁbrotic eﬀects within the heart including induction of ﬁbroblast hyperplasia,
activation of collagen biosynthetic pathways, and inhibition of collagen
degradative pathways (Fig. 2). In addition, available data indicate that these
eﬀects may result from either the direct action of ANGII or a synergistic
cooperation between this peptide and other proﬁbrotic factors.
Stimulation of ﬁbroblast proliferation
In vitro studies of rat and human cardiac ﬁbroblasts have shown that
ANGII stimulates cell proliferation by the AT1 receptor [54]. Results in the
literature indicate that the proliferative response of ﬁbroblasts to ANGII
might well be mediated by stimulation of the synthesis of growth or in-
ﬂammatory substances like platelet-derived growth factor and cytokines,
by integrin activation caused by adhesion proteins, or by a combination of
these mechanisms [55,56].
For instance, ANGII strongly up-regulates the expression of osteopontin
and its ligand aVb3 integrin in rat and human cardiac cells [57,58]. Inter-
estingly, elevated left ventricular osteopontin expression has been reported
in the Ren2 rat model characterized by high myocardial ANGII concen-
trations [49]. Monoclonal antibodies directed against either osteopontin
or aVb3 completely blocked the mitogenic eﬀect of ANGII on cultured rat
Fig. 2. Potential pathways involved in angiotensin II (ANG II)-mediated ﬁbrosis.
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ﬁbroblast proliferation acting by an integrin-dependent pathway.
Stimulation of collagen synthesis
Although diﬀerent signaling pathways of the AT1 receptor may subserve
direct ANGII-induced collagen synthesis in cardiac ﬁbroblasts [59], re-
cent data suggest that the MAP/ER kinase pathway seems to play a major
role [60]. The end result of signaling mechanisms is activation of transcrip-
tion factors, which bind to various cis-acting elements in the regulatory
sequences of a1 and a2 collagen type I and a1 collagen type III genes [60,61].
This, in turn, couples with gene expression and the synthesis of collagen
types I and III precursor molecules [62,63].
A number of studies, however, provide strong evidence that ANGII indi-
rectly regulates collagen synthesis by cardiac ﬁbroblasts by speciﬁc growth
factors [64]. The principal candidates include TGF-b1 and endothelin-1.
In fact, ANGII has been shown to induce collagen type I gene expression
by activation of TGF-b1 signaling pathways (eg, connective tissue growth
factor and Smad proteins) and these eﬀects were blocked by the AT1 re-
ceptor antagonist losartan [65]. ANGII has been also shown to increase the
expression of TGF-b1 in cultured cardiac ﬁbroblasts by stimulation of the
AT1 [54]. Recent data suggest that a Kru¨ppel-like zinc-ﬁnger transcription
factor 5 (also known as BTEB2 and IKLF) is critically involved in ANGII-
induced TGF-b1 expression, collagen synthesis, and development of car-
diac ﬁbrosis [66]. Besides up-regulation of cardiac gene TGF-b1 expression,
ANGII has been reported to convert latent TGF-b1 to the active protein in
vivo in the heart [67].
Endothelin-1 is synthesized and released by cardiac ﬁbroblasts in response
to the interaction of ANGII with the AT1 receptor [68] and has been shown
to stimulate the synthesis of collagen types I and III in these cells [69]. In
several rat models of arterial hypertension, blockade of endothelin receptors
is associated with decrease in left ventricular collagen accumulation [70,71].
There is some in vivo evidence that ANGII also inﬂuences post-
translational processing of cardiac ﬁbrillar collagen. It has been shown that
ANGII infusion is associated with stimulation of prolyl 4-hydroxylase
(an enzyme that mediates hydroxylation of procollagen a chains in the
endoplasmic reticulum of cardiac ﬁbroblasts) in the rat left ventricle [72]. In
addition, it has been reported that immunoreactive prolyl 4-hydroxylase
concentration decreases signiﬁcantly in the ventricle of post–myocardial
infarction rats treated with the AT1 receptor antagonist losartan [73].
Inhibition of collagen degradation
In addition to collagen synthesis, ANGII stimulation of the AT1 receptor
has been shown to regulate collagen degradation by attenuating interstitial
collagenase activity in adult rat [54] and human [74] cardiac ﬁbroblasts and
by enhancing TIMP-1 production in rat heart endothelial cells [75].
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cardiac collagen degradation (eg, TGF-b1 and plasminogen activator
inhibitor-1). Cell culture studies on human ﬁbroblasts show that exposure
of these cells to TGF-b1 in the presence of other growth factors (eg, epi-
dermal growth factor and basic ﬁbroblastic growth factor) resulted in down-
regulation of collagenase and up-regulation of TIMP-1 [76,77]. Similar
ﬁndings have been reported in the ﬁbrotic myocardium of TGF-b1 transgenic
mice [78].
Activation of the AT1 receptor in human cardiac ﬁbroblasts has been
shown to promote stimulation of plasminogen activator inhibitor-1 expres-
sion [79]. This stimulatory eﬀect has been conﬁrmed in the left ventricle of
ANGII-induced hypertensive rats [80]. Plasminogen activator inhibitor-1
inhibits the activation of collagenase and other matrix metalloproteinases
and thereby collagen degradation [81,82].
Interaction with aldosterone
Experimental studies have demonstrated the central role of aldosterone in
promoting cardiac ﬁbrosis, probably through a direct action on the heart
mediated by cardiac mineralocorticoid receptors [83–85]. In fact, aldoste-
rone has been shown to stimulate collagen synthesis through the miner-
alocorticoid receptor in isolated cardiac ﬁbroblasts [86]. In experimental
studies on rats with renovascular hypertension, hyperaldosteronism, or spon-
taneous hypertension, however, the aldosterone antagonist spironolactone
was able to prevent or reverse the development of myocardial ﬁbrosis even
though the drug did not normalize blood pressure and did not prevent LVH
[8,43,87–89]. An increase in this mineralocorticoid may be a mechanism for
ANGII-induced cardiac ﬁbrosis in some forms of arterial hypertension.
Interestingly, an increase in the density of AT1 receptors has been ob-
served in the heart of aldosterone-salt–treated rats [90]. In addition, the
AT1 receptor antagonist losartan prevents ﬁbrosis and up-regulation of
collagen types I and III mRNAs in the heart of aldosterone-salt–treated rats
[91]. Taken together, these ﬁndings support the hypothesis that one mechan-
ism by which aldosterone induces cardiac ﬁbrosis involves ANGII acting
through AT1 receptors. Because the production of aldosterone is activated
in the hypertrophied left ventricle of rats with spontaneous hypertension [92]
and hypertensive patients [93], it is possible that aldosterone contributes to
ANGII-mediated myocardial ﬁbrosis in primary hypertension.
The potential clinical relevance of these interactions is given by several
observations. In essential hypertension, a low dose of the aldosterone anta-
gonist canrenone added to antihypertensive treatment has been shown
signiﬁcantly to improve left ventricular diastolic function [94]. This improve-
ment, not accounted for by changes in blood pressure and left ventricular
mass, can be ascribed to a direct action of the drug on the myocardium. This
is further supported by recent studies showing that chronic administration
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with a reduction in the circulating levels of markers of collagen turnover in
patients with diﬀerent cardiac diseases that evolve with myocardial ﬁbrosis.
Summary
Structural homogeneity of cardiac tissue is governed by mechanical
and humoral factors that regulate cell growth, apoptosis, phenotype, and
extracellularmatrix turnover.ANGII has endocrine, autocrine, andparacrine
properties that inﬂuence the behavior of cardiac cells and matrix by AT1
receptor binding. Various paradigms have been suggested, including ANGII-
mediated up-regulation of collagen types I and III formation anddeposition in
cardiac conditions, such asHHD.Agrowing body of evidence, however, deals
with the potential role of aldosterone, either local or systemic, in inducing
cardiac ﬁbrosis. Aldosterone might also mediate the proﬁbrotic actions of
ANGII. To reduce the risk of heart failure that accompaniesHHD, its adverse
structural remodeling (eg, myocardial hypertrophy and ﬁbrosis) must be
targeted for pharmacologic intervention. Cardioprotective agents must
reverse not only the exaggerated growth of cardiac cells, but also regress
existing abnormalities in ﬁbrillar collagen.Available experimental and clinical
data suggest that agents interfering with ACE, the AT1 receptor, or the
mineralocorticoid receptor may provide such a cardioprotective eﬀect.
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